terazosin / Generic mfg. - LARVOL DELTA

TAME-PD:: Terazosin And Metabolic Energetics in Parkinson's Disease (clinicaltrials.gov) - P2 | N=120 | Suspended | Sponsor: Nandakumar Narayanan | Initiation date: Jul 2026 ➔ Jul 2028 | Not yet recruiting ➔ Suspended

Trial initiation date • Trial suspension • CNS Disorders • Movement Disorders • Parkinson's Disease

Terazosin Alleviates Apoptosis and Neuroinflammation in Cerebral Ischemia-reperfusion Injury via Activating the PI3K/AKT/mTOR Signaling Pathway. (PubMed, Curr Neuropharmacol) - "In summary, this study demonstrates that TZ exerts neuroprotective effects against CIRI by activating the PI3K/AKT/mTOR signaling pathway. These results provide a preclinical basis for repurposing TZ as a treatment for ischemic stroke and highlight the PI3K/AKT/mTOR axis as a potential neuroprotective target."

IO biomarker • Journal • Cardiovascular • CNS Disorders • Inflammation • Ischemic stroke • Reperfusion Injury • BAX • BCL2 • IL1B • IL6 • PIK3CA • TNFA

Glycolytic Reprogramming in Parkinson's Disease: From Bioenergetic Crosstalk to Therapeutic Modulation. (PubMed, Med Res Rev) - "By bridging these mechanistic insights with cross-disease metabolic links to type 2 diabetes and oncology, we evaluate the therapeutic potential of emerging metabolic modulators, including terazosin, cordycepin, and GLP-1 receptor agonists. Finally, we outline the pressing translational bottlenecks, particularly blood-brain barrier penetrance and cell-specific targeting, which must be overcome to successfully harness glycolytic modulation as a disease-modifying strategy for neurodegenerative disorders."

Journal • Review • CNS Disorders • Diabetes • Inflammation • Metabolic Disorders • Movement Disorders • Oncology • Parkinson's Disease • Proteinopathy • Type 2 Diabetes Mellitus • PTEN

TAME-AD: Terazosin And Metabolic Engagement in Alzheimer's Disease (clinicaltrials.gov) - P2 | N=100 | Not yet recruiting | Sponsor: Qiang Zhang

New P2 trial • Alzheimer's Disease • CNS Disorders

TZ-ALS: Effect of Terazosin on ATP Levels in People With Amyotrophic Lateral Sclerosis (clinicaltrials.gov) - P1 | N=20 | Recruiting | Sponsor: University of Iowa | Not yet recruiting ➔ Recruiting | Trial completion date: May 2027 ➔ Oct 2027 | Initiation date: May 2026 ➔ Aug 2026 | Trial primary completion date: May 2027 ➔ Aug 2027

Enrollment open • Trial completion date • Trial initiation date • Trial primary completion date • Amyotrophic Lateral Sclerosis • CNS Disorders

TRAM: Comparison of Alpha Blockers (Terazosin and Tamsulosin) in Reducing Ureteral Stent Related Symptoms (clinicaltrials.gov) - P3 | N=150 | Recruiting | Sponsor: Penang Hospital, Malaysia | Trial primary completion date: May 2026 ➔ May 2027 | Trial completion date: May 2026 ➔ Jul 2027

Trial completion date • Trial primary completion date

Epidemiology, Safety of Dilation, and Medication-Associated Risk of Acute Angle-Closure Crisis in the United States. (PubMed, Am J Ophthalmol) - "AACC following pharmacologic dilation was rare and occurred predominantly among patients with anatomical risk factors, supporting the safety of dilation in routine clinical care. Medication-associated risk signals were observed across commonly prescribed drugs at the population level, including previously unreported associations, highlighting the importance of proactive ocular risk assessment and medication reconciliation in anatomically predisposed patients. Novel medication associations with calcium channel blockers, CGRP monoclonal antibodies, and PCSK9 inhibitors warrant further investigation."

Journal • Glaucoma • Ophthalmology

Impact of the national centralized volume-based procurement policy on antihypertensive drug procurement, price, and volume in Guangxi: an interrupted time series analysis of procurement data. (PubMed, Front Pharmacol) - "Monthly procurement data for four NVBP antihypertensive drugs (Olmesartan Medoxomil, Candesartan Cilexetil, Terazosin Hydrochloride, and Indapamide) were collected from January 2019 to April 2021, covering 16 months before and 12 months after policy implementation (May 1, 2020). These findings, based on procurement records rather than patient-level data, suggest that price reductions alone may not ensure consistent procurement patterns. Strengthening supply chain resilience and aligning procurement schedules with clinical demand may support more stable drug supply in disadvantaged regions."

Journal • Cardiovascular • Hypertension

Ge-Gen Decoction Modulates the HSP90/AKT Signaling Pathway and the NLRP3 Inflammasome to Alleviate Primary Dysmenorrhea. (PubMed, J Pain Res) - "Rats were divided into five groups (n = 6 each): control, PDM model, GGD (1.8 g/kg), GGD plus Terazosin (an HSP90 agonist, 0.08 g/kg), and ibuprofen (0.06 g/kg). GGD alleviates cold-damp stagnation-type PDM in a rat model. The findings suggest that its mechanism involves modulation of the HSP90/AKT pathway, thereby suppressing NLRP3 inflammasome activation and subsequent pro-inflammatory cytokine release."

Journal • Women's Health • CDC37 • HSP90AA1 • IL18 • IL1B • IL6 • NLRP3

Glycolysis-enhancing α1-adrenergic antagonists have therapeutic potential in Alzheimer's disease. (PubMed, Alzheimers Res Ther) - "These data provide preliminary evidence that glycolysis-enhancing drugs have therapeutic potential in AD."

Journal • Alzheimer's Disease • Benign Prostatic Hyperplasia • Cardiovascular • CNS Disorders • Cognitive Disorders • Hypertension • Aβ42

A QbD-based method for the simultaneous determination of tadalafil, terazosin, and tamsulosin using organic-solvent free mixed-micellar HPLC: a sustainable green approach. (PubMed, BMC Chem) - "The approach was effectively utilized to identify analytes in the formulated tablets and pharmaceutical products. The ecological impact of the method was evaluated using the complex green analytical procedure index and Analytical GREEnness metrics, demonstrating the advantages of the proposed procedure over previously reported methods."

Journal • Benign Prostatic Hyperplasia

Ethnopharmacological Validation of the Antinociceptive Potential ofCalotropis giganteaL. Flowers: Phytochemical Characterization, Safety Evaluation, and Mechanistic Insights from In Vivo Models. (PubMed, J Ethnopharmacol) - "The findings provide pharmacological evidence supporting the traditional use of C. gigantea in pain management. The antinociceptive effects may be associated with the synergistic action of phenolic and flavonoid constituents through modulation of multiple nociceptive pathways. CGEE also demonstrated a favorable safety profile, supporting its potential as a source of novel antinociceptive agents."

Journal • Preclinical • Addiction (Opioid and Alcohol) • Cough • Inflammation • Pain • Respiratory Diseases • Thermal Injury

The EJS ACT-PD Multi-arm, Multi-stage Platform Trial: Assessing Potential Disease-Modifying Therapies for Parkinson’s Disease (EAN 2026) - "Participants will be randomised to telmisartan, terazosin, or placebo, with a third treatment arm (ursodeoxycholic acid) opening in 2026. EJS ACT-PD is set to become the world's largest Parkinson's disease trial, providing an efficient platform to evaluate multiple DMTs while generating an extensive dataset to advance understanding of disease progression."

CNS Disorders • Movement Disorders • Parkinson's Disease

A Propensity Score-Matched Protocol: Terazosin Plus Finasteride For Benign Prostatic Hyperplasia - Sex Hormone And Urinary Control Effects. (PubMed, J Vis Exp) - "Safety profiles were comparable (P > 0.05). The terazosin‑- finasteride regimen is associated with improved long-term outcomes, better urinary control, and favorable hormonal changes, though hormonal effects are primarily attributable to finasteride."

Journal • Retrospective data • Benign Prostatic Hyperplasia

Disproportionality analysis of drug-associated tinnitus safety signals: a 43-year pharmacovigilance study. (PubMed, Naunyn Schmiedebergs Arch Pharmacol) - "The strongest signal was diphenhydramine citrate/ibuprofen (ROR 10.71), followed by chloroquine phosphate (9.28)...This 43-year analysis identifies 74 positive drug-associated tinnitus signals, including novel immunobiologic (guselkumab, lifitegrast) and cardiovascular (lovastatin, terazosin) associations without current audiological labelling warnings. The delayed onset profile implicates cumulative cochlear injury mechanisms. These findings provide an actionable basis for regulatory prioritisation and prospective audiological safety research for drug classes where audiological monitoring protocols are currently absent."

Adverse events • Journal • Cardiovascular • Otorhinolaryngology • ROR1

Terazosin Attenuates Neuronal Pyroptosis by Regulating the Mitochondrial ROS/NLRP3 Inflammasome Axis Through Mitophagy in Cerebral Ischemia-Reperfusion Injury. (PubMed, Kaohsiung J Med Sci) - "Importantly, blockade of mitophagy or activation of NLRP3 weakened the protective effects of TZ. Collectively, these findings indicate that TZ mitigates CI/RI-induced neuronal injury by enhancing mitophagy and inhibiting ROS/NLRP3-dependent pyroptosis."

Journal • Cardiovascular • Ischemic stroke • Reperfusion Injury • BECN1 • IL18 • IL1B • NLRP3

EJS ACT-PD: The world’s first multi-arm, multi-stage platform trial assessing potential disease-modifying therapies for Parkinson’s disease (WPC 2026) - "The trial will launch with two active treatments arms (telmisartan and terazosin) against a shared placebo. A third active treatment arm (ursodeoxycholic acid) will open after 1 year... Recruitment launched in September 2025 with sites gradually opening over the next 6-9 months. The trial will provide ongoing research opportunity for PwP, strengthen UK PD trials infrastructure, and provide replicable processes for future research initiatives."

Alzheimer's Disease • CNS Disorders • Dementia • Movement Disorders • Parkinson's Disease

Integrative In Silico Identification of TP53-Associated Drug Repurposing Candidates in Lung Adenocarcinoma. (PubMed, Pharmaceuticals (Basel)) - "Additionally, LUAD cell lines displayed consistent sensitivity signals for dropropizine (p = 8.47 × 10-3), terazosin (p = 1.11 × 10-3), morantel (p = 9.05 × 10-3), netilmicin (p = 8.37 × 10-3), altretamine (p = 9.82 × 10-3), and perphenazine (p = 9.58 × 10-3). Based on TP53-associated drug sensitivity profiles, this in silico analysis identifies atropine among the prioritized candidates, showing the strongest TP53-associated sensitivity signal in LUAD cell lines. Although experimental validation is required, the integration of independent computational datasets provides a robust framework for candidate prioritization and our findings provide a rationale for further preclinical investigation of atropine and related compounds in LUAD."

Journal • Lung Adenocarcinoma • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • TP53

Comparative Safety Profiles of a1-Adrenergic Blockers in Men with LUTS: Insights from a FAERS Disproportionality Study (AUA 2026) - "After deduplication per FDA guidance, only male cases listing alfuzosin, doxazosin, tamsulosin, terazosin, or silodosin as the primary suspect drug were included. This large-scale FAERS analysis reveals distinct safety fingerprints within the α-blocker class. Highly selective agents (tamsulosin, silodosin) were characterised by strong ejaculatory and ocular signals, whereas less selective agents (terazosin, doxazosin) displayed prominent vasodilatory patterns. These findings complement clinical evidence and support individualised α-blocker selection based on patient comorbidities and treatment priorities."

Clinical • Hypotension • Ophthalmology

Effects of tamsulosin 0.2mg or terazosin 5mg administration on post micturition dribbling (PMD) in men with lower urinary tract symptoms: A Prospective, open-label, Efficacy-evaluation Study (AUA 2026) - "α-Blockers, standard treatments for male lower urinary tract symptoms, may be considered for the management of PMD. Terazosin demonstrated superior efficacy over tamsulosin in improving PMD symptoms and was well tolerated."

Clinical

Terazosin as a Non-Hormonal Treatment for Endometriosis. (PubMed, Int J Mol Sci) - "NF-κB decreased in tissue and serum (p < 0.001) but not in peritoneal fluid (p = 0.206). Overall, terazosin produced leuprolide-like molecular benefits without hormonal suppression, supporting repurposing as a candidate non-hormonal therapy, while highlighting the need for longer-duration studies and randomized clinical trials given model and pain-assessment limitations."

Clinical • Journal • Endometriosis • Gynecology • Inflammation • Pain • Women's Health • CXCL8 • HIF1A • IL6 • NFKB1 • TNFA

Not Just For Nightmares: Literature Review Assessing the Alpha-1 Antagonist's Role in PTSD-Associated Flashbacks. (APA 2026) - "Search terms included prazosin and flashbacks, doxazosin and flashbacks, terazosin and flashbacks, alpha-antagonist and flashbacks, alpha-1 antagonist and flashbacks, alpha blockers and flashbacks, alpha blockers and re-experiencing, alpha-1 antagonists and re-experiencing, doxazosin and re-experiencing, prazosin and re-experiencing, terazosin and re-experiencing. Using these terms, 18 publications were identified, of which four met the inclusion criteria. Reasons for exclusion included the main treatment modality not being an alpha-1 antagonist or the primary symptom being examined not being PTSD-associated flashbacks. All four articles meeting criteria utilized prazosin as a treatment modality, with two using prazosin as monotherapy and the others using doxazosin and/or prazosin with another psychotropic medication."

Review • CNS Disorders • Mood Disorders • Post-traumatic Stress Disorder

Bilateral Pheochromocytoma Presenting with Severe Hypercalcemia In a Patient With Congenital Hypoplastic Left Heart Syndrome (AACE 2026) - "Bilateral pheochromocytomas are typically managed with surgical resection after α-blockade—preferably phenoxybenzamine, or alternatives such as doxazosin, prazosin, or terazosin—followed by β-blockers. For nonsurgical or unresectable cases, treatment options include peptide"

Clinical • Cardiovascular • Congestive Heart Failure • Endocrine Disorders • Heart Failure • Metabolic Disorders • Solid Tumor • EPAS1

The Candy that Crushed Potassium - Licorice Induced Apparent Mineralocorticoid Excess (AACE 2026) - "Medications included carvedilol, hydrochlorothiazide, and terazosin. The excess cortisol binds to mineralocorticoid receptors in the kidneys, causing sodium retention and potassium wasting. Hypokalemia improves within 24 to 72 hours of stopping licorice, with full recovery in 1 to 2 weeks;"

Cardiovascular • CNS Disorders • Dyslipidemia • Hypertension • Metabolic Disorders • Migraine

Terazosin drives sex-dependent adrenergic-bioenergetic reprogramming to restore network function in Alzheimer's disease. (PubMed, bioRxiv) - "Moreover, TZ rescued spatial cognition in transgenic rats, with cognitive gains seemingly more pronounced in females. These results support adrenergic-bioenergetic modulation as a translational strategy for early-stage AD and underscore the necessity of sex as a biological variable in disease-modifying treatment development."

Journal • Alzheimer's Disease • CNS Disorders